M.S. in Biotechnology Management and Entrepreneurship Making the World Smarter, Safer and Healthier Request More Info Attend an Info Session Contact Us Artificial Intelligence Biotechnology Computer Science Cybersecurity Data Analytics and Visualization Digital Marketing and Media Mathematics Occupational Therapy Physician Assistant Physics Speech-Language Pathology Eligible for STEM-OPT Affordable Fixed-Rate Tuition $30K After STEM Fellows Scholarship QS Rankings #63 University in the U.S. Alumni Career Outcomes 95% employed within 6 months M.S. in Biotechnology Management & Entrepreneurship12 Courses I On-消消犯 in New York City I Full-Time or Part-Time The 36-credit M.S. in Biotechnology Management and Entrepreneurship is an interdisciplinary program designed specifically for the workforce needs of the biotechnology industry. This highly competitive program impacts society in the areas of food, fuel and health. In this program, you'll master the mission-critical scientific, technical and business knowledge needed to launch, manage, scale and commercialize biotechnology innovations and delivery systems. Youll learn what it takes to shepherd a great idea through regulations, clinical trials, compliance and patents. And you'll merge your knowledge of science, technology and business, such as marketing, customer development, analytics and new business development, to effectively bring pharma and biotech products to market. From developing vaccines for infectious diseases, such as COVID-19, to commercializing CRISPR-edited genetic material for pesticide-resistant crops, biotech entrepreneurs are improving global health conditions and the quality of life for millions of people. And the industry is booming. Startups, large-multinational companies and leading medical and research facilities are seeking managers of new products, projects, business development, regulatory and compliance, and clinical trials. Secure your place in this fast-growing, high-paying job market with the M.S. in Biotechnology Management and Entrepreneurship. Program Highlights Gain business and entrepreneurship skills, such as new business development, marketing, finance for startups and business analytics and learn to lead product, program and project management across the biotechnology ecosystem. Design and conduct company-sponsored research on topics impacting the pharmaceutical and biotech industries or work alongside faculty in university labs. 95% graduate employment rate within six months of graduation: our alumni land dream jobs in business development, product and project management, clinical trials management, life science consulting, commercialization, and marketing with top companies like Merck, Kantar Health, BioMarin, New York Stem Cell Foundation, Lucerna, and SFA Therapeutics. Top-ranked university in the heart of NYC: #63 in the U.S. by QS World and #1 Best Value in New York by U.S. News. STEM-OPT: International 消消犯 may be eligible for up to 3 years of Optional Practical Training (OPT). $30K total tuition after STEM Fellows Scholarship, plus the opportunity to showcase research at the Katz School's Symposium on Science, Technology and Health. Full Program Breakdown M.S. in Biotechnology Management & Entrepreneurship12 Courses I On-消消犯 in New York City I Full-Time or Part-Time The 36-credit M.S. in Biotechnology Management and Entrepreneurship is an interdisciplinary program designed specifically for the workforce needs of the biotechnology industry. This highly competitive program impacts society in the areas of food, fuel and health. In this program, you'll master the mission-critical scientific, technical and business knowledge needed to launch, manage, scale and commercialize biotechnology innovations and delivery systems. Youll learn what it takes to shepherd a great idea through regulations, clinical trials, compliance and patents. And you'll merge your knowledge of science, technology and business, such as marketing, customer development, analytics and new business development, to effectively bring pharma and biotech products to market. From developing vaccines for infectious diseases, such as COVID-19, to commercializing CRISPR-edited genetic material for pesticide-resistant crops, biotech entrepreneurs are improving global health conditions and the quality of life for millions of people. And the industry is booming. Startups, large-multinational companies and leading medical and research facilities are seeking managers of new products, projects, business development, regulatory and compliance, and clinical trials. Secure your place in this fast-growing, high-paying job market with the M.S. in Biotechnology Management and Entrepreneurship. Program Highlights Gain business and entrepreneurship skills, such as new business development, marketing, finance for startups and business analytics and learn to lead product, program and project management across the biotechnology ecosystem. Design and conduct company-sponsored research on topics impacting the pharmaceutical and biotech industries or work alongside faculty in university labs. 95% graduate employment rate within six months of graduation: our alumni land dream jobs in business development, product and project management, clinical trials management, life science consulting, commercialization, and marketing with top companies like Merck, Kantar Health, BioMarin, New York Stem Cell Foundation, Lucerna, and SFA Therapeutics. Top-ranked university in the heart of NYC: #63 in the U.S. by QS World and #1 Best Value in New York by U.S. News. STEM-OPT: International 消消犯 may be eligible for up to 3 years of Optional Practical Training (OPT). $30K total tuition after STEM Fellows Scholarship, plus the opportunity to showcase research at the Katz School's Symposium on Science, Technology and Health. Swipe to learn more! M.S. in Biotechnology Management & Entrepreneurship12 Courses I On-消消犯 in New York City I Full-Time or Part-Time The 36-credit M.S. in Biotechnology Management and Entrepreneurship is an interdisciplinary program designed specifically for the workforce needs of the biotechnology industry. This highly competitive program impacts society in the areas of food, fuel and health. In this program, you'll master the mission-critical scientific, technical and business knowledge needed to launch, manage, scale and commercialize biotechnology innovations and delivery systems. Youll learn what it takes to shepherd a great idea through regulations, clinical trials, compliance and patents. And you'll merge your knowledge of science, technology and business, such as marketing, customer development, analytics and new business development, to effectively bring pharma and biotech products to market. From developing vaccines for infectious diseases, such as COVID-19, to commercializing CRISPR-edited genetic material for pesticide-resistant crops, biotech entrepreneurs are improving global health conditions and the quality of life for millions of people. And the industry is booming. Startups, large-multinational companies and leading medical and research facilities are seeking managers of new products, projects, business development, regulatory and compliance, and clinical trials. Secure your place in this fast-growing, high-paying job market with the M.S. in Biotechnology Management and Entrepreneurship. Gain business and entrepreneurship skills, such as new business development, marketing, finance for startups and business analytics and learn to lead product, program and project management across the biotechnology ecosystem. Design and conduct company-sponsored research on topics impacting the pharmaceutical and biotech industries or work alongside faculty in university labs. 95% graduate employment rate within six months of graduation: our alumni land dream jobs in business development, product and project management, clinical trials management, life science consulting, commercialization, and marketing with top companies like Merck, Kantar Health, BioMarin, New York Stem Cell Foundation, Lucerna, and SFA Therapeutics. Top-ranked university in the heart of NYC: #63 in the U.S. by QS World and #1 Best Value in New York by U.S. News. STEM-OPT: International 消消犯 may be eligible for up to 3 years of Optional Practical Training (OPT). $30K total tuition after STEM Fellows Scholarship, plus the opportunity to showcase research at the Katz School's Symposium on Science, Technology and Health. View Curiculum Program Links Curriculum Faculty Research Student Life Mission and Goals Learn More Admissions & Financial Aid Graduate Admissionskatzgrad@yu.edu646-592-4753General Inquirieskatz@yu.eduJoin our Community Application Information Candidates must possess a bachelor's degree from an accredited college or university.Visit Graduate Admissions for up-to-date application requirements and deadlines. Questions? if you have questions about your qualifications, financial aid opportunitiesand financing your graduate degree. We can do a preliminary transcript review and discuss your admissions and financing options with the Katz School.B.A./M.S. Pathways OptionThrough the B.A./M.S. program, undergraduates from Yeshiva College and Stern College for Women can take up to nine graduate credits that count toward both the bachelors and master's degrees. After completing the bachelors, 消消犯 can finish the graduate degree in just one more year. Learn more at yu.edu/pathways.Tuition, Financial Aid and Scholarships The Office of Student Finance maintains current tuition and fees for all graduate programs. All applicants are automatically considered for the program. You do not need to submit any additional information. Learn More Graduate Admissionskatzgrad@yu.edu646-592-4753General Inquirieskatz@yu.eduJoin our Community Admissions & Financial Aid Application Information Candidates must possess a bachelor's degree from an accredited college or university.Visit Graduate Admissions for up-to-date application requirements and deadlines. Questions? if you have questions about your qualifications, financial aid opportunitiesand financing your graduate degree. We can do a preliminary transcript review and discuss your admissions and financing options with the Katz School.B.A./M.S. Pathways OptionThrough the B.A./M.S. program, undergraduates from Yeshiva College and Stern College for Women can take up to nine graduate credits that count toward both the bachelors and master's degrees. After completing the bachelors, 消消犯 can finish the graduate degree in just one more year. Learn more at yu.edu/pathways.Tuition, Financial Aid and Scholarships The Office of Student Finance maintains current tuition and fees for all graduate programs. All applicants are automatically considered for the program. You do not need to submit any additional information. Meet our Students Christine Chery '25 on the Commercialization Potential for Novel Cancer Treatment JunAPDeveloped by Sapience Therapeutics, Inc., JunAP is a cutting-edge peptide antagonist that inhibits the AP-1 transcription factor complex, a key player in oncogenesis and immune suppression. Natania Birnbaum '24 on Duckweed's Potential for Sustainable, Space-Based Food ProductionDuckweed is a small, fast-growing, nutritionally dense aquatic plant thats being investigated for human consumption and for growing in outer space. Under the guidance of professor Robert Friedman and industry mentor John McShane, MS '21, Natania conducted a comprehensive survey of duckweed biology, genetics, and cultivation methods and charted the current economic landscape and future projections for the duckweed market. Meet the Faculty Dr. Oliveira is Advancing Medical Technologies with the Power of Marine Bioluminescent EnzymesFrom deep-sea bioluminescence to antifreeze proteins, Dr. Anderson Garbuglio de Oliveira's trailblazing research is set to advance disease detection, allowing for earlier diagnoses and improved patient outcomes. Dr. Jochen Raimann's Cutting-Edge Epidemiological Research in DialysisIndustry professor of biotechnology, Dr. Raimann, has been a full-time scientist at the Renal Research Institute (RRI) since 2007. As RRI's director of data analytics, he conducts epidemiological research in dialysis, oversees research database management and national and international data transfers. RECENT RESEARCH Program News Researchers Develop Algorithms to Assist in Stroke Recovery Read about the study Researchers Develop Algorithms to Assist in Stroke Recovery Researchers have developed a series of algorithms using Siamese networks, a type of artificial intelligence, to better identify and track the body movements of stroke patients in order to assist in patient treatment and recovery. Read about the story in the Katz School blog. Weill Cornell, Biotech Highlights Graduate Student Research Read about the research Weill Cornell, Biotech Highlights Graduate Student Research Collaborations, like the one between Weill Cornell Medicine and the Katz Schools M.S. in Biotechnology Management and Entrepreneurship, have emerged as catalysts for the development of the next generation of drugs, devices and services. Read the story in the Katz School blog. Less Dietary Sodium Key to Protecting Kidney Disease Patients Read about the paper's results Less Dietary Sodium Key to Protecting Kidney Disease Patients Managing an intricate balance between sodium intake, blood pressure and the volume of bodily fluid is key to minimizing the risk of further harm to individuals with end-stage kidney disease, according to a paper co-authored by Dr. Jochen Raimann, an industry professor in the M.S. in Biotechnology Management and Entrepreneurship.Read about the story in the Katz School blog. Alum's Kit Tests for Miscarriage Causes Read more about Rebecca's product idea Alum's Kit Tests for Miscarriage Causes Alumna Rebecca Russo-Schlossberg is developing an at-home miscarriage test kit for her own startup Genosa Diagnostics. More than half of miscarriages are the result of chromosomal abnormalities in the fertilized egg, which can cause developmental problems that result in an unviable fetus. Russo-Schlossbergs test would be important because individuals who miscarry in their first trimester typically do so at home and thus dont have the opportunity to genetically test the fetal tissue to determine a cause.Read the entire story here. Biotech Professor Writes Book on Innovation Read about what inspired Lorraine Marchand Biotech Professor Writes Book on Innovation In The Innovation Mindset, Lorraine Marchand shares her , a formula for driving significant and lasting transformation in any organization. Marchand emphasizes the frame of mind needed to spark the innovation process, underscoring the importance of creating a problem-solving culture and supporting personal curiosity, passion and talent.. Students Targeting SUMO Proteins in Male Infertility Read about the YU-Katz Biotech research partnership Students Targeting SUMO Proteins in Male Infertility A 消消犯 researcher and several Katz School graduate 消消犯 will investigate how inhibiting the function of a cluster of small proteins in testicular cells affects spermatogenesis, or the production and regulation of sperm. The research is being supported in part by a grant from YUs Provost Faculty Research Fund awarded to biotechnology Program Director Dr. Rana Kahn.Read entire story on the Katz blog. Sloan Kettering Hires Biotechnology Graduate Read more about Shanza Tariq's experience Sloan Kettering Hires Biotechnology Graduate When Shanza Baseer Tariq graduated in May with a masters degree in biotechnology, she already had a publication track record and a job waiting for her as a research assistant at Memorial Sloan Kettering Cancer Center.. Market Analysis Finds Commercial Promise for Cancer Drug Read more about the research Market Analysis Finds Commercial Promise for Cancer Drug Avi Strauss, a recent Katz School biotech graduate, has performed a detailed market analysis on a new drug therapy for colorectal cancer. The analysis recommended that Sapience Therapeutics, a New York-based biotech company, develop a molecule called a novel beta-catenin antagonist for treatment of the cancer. Beta-catenin is part of the Wnt signaling pathway, which promotes tumor growth and suppresses the immune system. In addition to colorectal cancer, Strauss reviewed four other types of cancer that have high mortality rates and resist conventional therapies: acute lymphocytic leukemia, breast cancer, melanoma, and multiple myeloma. He found that colorectal cancer patients would be a prime population for Sapiences novel peptide because of the high incidence of a mutation in the Wnt signaling pathway that results in its overactivation and leads to the formation of cancer. Colorectal cancer presents the highest upside according to the revenue projection model, said Strauss, who is a healthcare consultant for the Marwood Group, and presents the largest potential available population among the five cancer types studied. Sapiences therapeutic approach, according to Dr. Kappel, is to target protein-protein interactions (PPIs) that seem necessary to the survival of cancer or that inhibit the immune systems response to cancerous tumors. The interactions targeted by Sapience are considered undruggable due to the intracellular location of the PPIs, making them difficult to treat with small-molecule drugs such as chemotherapies that are incapable of disrupting PPIs, and biologic-based drugs like monoclonal antibodies that are too big to enter cells. Peptides combine the best properties of small and large molecules, said Dr. Kappel, and present an opportunity to disrupt intracellular PPIs and to reduce mortality in cancer patients and possibly in other diseases. Robert Friedman, an adjunct professor in the biotechnology program and Strausss advisor, said that Strausss presentation demonstrates the strength of the molecule-to-market nature of the Katz Schools biotechnology program and its emphasis on understanding the science, and translating it into practical and actionable decisions. Avis understanding of the science, clinical development and the market were all critical to successfully completing the project, he said. The piece de resistance of his elegant work is undoubtedly the market forecast model that the client will incorporate in its corporate planning process for years to come. New York City a Hub for Biotech Innovation Read more about the city's $500 million investment New York City a Hub for Biotech Innovation Four of the top 10 biopharma clusters are located in the New York area. New York Citys Economic Development Corporation has started investing $500 million into LifeSciNYC, an initiative enshrining New York as a global leader in life sciences innovation and R&D. The initiative is also attracting entrepreneurs from around the world who have started 4,000 companies. From deploying therapeutic glycoproteins to treat autoimmune diseases to commercializing CRISPR-edited genetic material for pesticide-resistant crops, biotech entrepreneurs are improving global health conditions and the quality of life for millions of people. Startups, large multinational companies and leading medical and research facilities are seeking managers of new products, projects, business development, regulatory and compliance, and clinical trials. Secure your place in this fast-growing, high-paying job market with a masters in biotechnology management and entrepreneurship. Researchers Develop Algorithms to Assist in Stroke Recovery Read about the study Researchers Develop Algorithms to Assist in Stroke Recovery Researchers have developed a series of algorithms using Siamese networks, a type of artificial intelligence, to better identify and track the body movements of stroke patients in order to assist in patient treatment and recovery. Read about the story in the Katz School blog. Weill Cornell, Biotech Highlights Graduate Student Research Read about the research Weill Cornell, Biotech Highlights Graduate Student Research Collaborations, like the one between Weill Cornell Medicine and the Katz Schools M.S. in Biotechnology Management and Entrepreneurship, have emerged as catalysts for the development of the next generation of drugs, devices and services. Read the story in the Katz School blog. Less Dietary Sodium Key to Protecting Kidney Disease Patients Read about the paper's results Less Dietary Sodium Key to Protecting Kidney Disease Patients Managing an intricate balance between sodium intake, blood pressure and the volume of bodily fluid is key to minimizing the risk of further harm to individuals with end-stage kidney disease, according to a paper co-authored by Dr. Jochen Raimann, an industry professor in the M.S. in Biotechnology Management and Entrepreneurship.Read about the story in the Katz School blog. Alum's Kit Tests for Miscarriage Causes Read more about Rebecca's product idea Alum's Kit Tests for Miscarriage Causes Alumna Rebecca Russo-Schlossberg is developing an at-home miscarriage test kit for her own startup Genosa Diagnostics. More than half of miscarriages are the result of chromosomal abnormalities in the fertilized egg, which can cause developmental problems that result in an unviable fetus. Russo-Schlossbergs test would be important because individuals who miscarry in their first trimester typically do so at home and thus dont have the opportunity to genetically test the fetal tissue to determine a cause.Read the entire story here. Biotech Professor Writes Book on Innovation Read about what inspired Lorraine Marchand Biotech Professor Writes Book on Innovation In The Innovation Mindset, Lorraine Marchand shares her , a formula for driving significant and lasting transformation in any organization. Marchand emphasizes the frame of mind needed to spark the innovation process, underscoring the importance of creating a problem-solving culture and supporting personal curiosity, passion and talent.. Students Targeting SUMO Proteins in Male Infertility Read about the YU-Katz Biotech research partnership Students Targeting SUMO Proteins in Male Infertility A 消消犯 researcher and several Katz School graduate 消消犯 will investigate how inhibiting the function of a cluster of small proteins in testicular cells affects spermatogenesis, or the production and regulation of sperm. The research is being supported in part by a grant from YUs Provost Faculty Research Fund awarded to biotechnology Program Director Dr. Rana Kahn.Read entire story on the Katz blog. Sloan Kettering Hires Biotechnology Graduate Read more about Shanza Tariq's experience Sloan Kettering Hires Biotechnology Graduate When Shanza Baseer Tariq graduated in May with a masters degree in biotechnology, she already had a publication track record and a job waiting for her as a research assistant at Memorial Sloan Kettering Cancer Center.. Market Analysis Finds Commercial Promise for Cancer Drug Read more about the research Market Analysis Finds Commercial Promise for Cancer Drug Avi Strauss, a recent Katz School biotech graduate, has performed a detailed market analysis on a new drug therapy for colorectal cancer. The analysis recommended that Sapience Therapeutics, a New York-based biotech company, develop a molecule called a novel beta-catenin antagonist for treatment of the cancer. Beta-catenin is part of the Wnt signaling pathway, which promotes tumor growth and suppresses the immune system. In addition to colorectal cancer, Strauss reviewed four other types of cancer that have high mortality rates and resist conventional therapies: acute lymphocytic leukemia, breast cancer, melanoma, and multiple myeloma. He found that colorectal cancer patients would be a prime population for Sapiences novel peptide because of the high incidence of a mutation in the Wnt signaling pathway that results in its overactivation and leads to the formation of cancer. Colorectal cancer presents the highest upside according to the revenue projection model, said Strauss, who is a healthcare consultant for the Marwood Group, and presents the largest potential available population among the five cancer types studied. Sapiences therapeutic approach, according to Dr. Kappel, is to target protein-protein interactions (PPIs) that seem necessary to the survival of cancer or that inhibit the immune systems response to cancerous tumors. The interactions targeted by Sapience are considered undruggable due to the intracellular location of the PPIs, making them difficult to treat with small-molecule drugs such as chemotherapies that are incapable of disrupting PPIs, and biologic-based drugs like monoclonal antibodies that are too big to enter cells. Peptides combine the best properties of small and large molecules, said Dr. Kappel, and present an opportunity to disrupt intracellular PPIs and to reduce mortality in cancer patients and possibly in other diseases. Robert Friedman, an adjunct professor in the biotechnology program and Strausss advisor, said that Strausss presentation demonstrates the strength of the molecule-to-market nature of the Katz Schools biotechnology program and its emphasis on understanding the science, and translating it into practical and actionable decisions. Avis understanding of the science, clinical development and the market were all critical to successfully completing the project, he said. The piece de resistance of his elegant work is undoubtedly the market forecast model that the client will incorporate in its corporate planning process for years to come. New York City a Hub for Biotech Innovation Read more about the city's $500 million investment New York City a Hub for Biotech Innovation Four of the top 10 biopharma clusters are located in the New York area. New York Citys Economic Development Corporation has started investing $500 million into LifeSciNYC, an initiative enshrining New York as a global leader in life sciences innovation and R&D. The initiative is also attracting entrepreneurs from around the world who have started 4,000 companies. From deploying therapeutic glycoproteins to treat autoimmune diseases to commercializing CRISPR-edited genetic material for pesticide-resistant crops, biotech entrepreneurs are improving global health conditions and the quality of life for millions of people. Startups, large multinational companies and leading medical and research facilities are seeking managers of new products, projects, business development, regulatory and compliance, and clinical trials. Secure your place in this fast-growing, high-paying job market with a masters in biotechnology management and entrepreneurship.